Somewhat Favorable News Coverage Somewhat Unlikely to Impact Medpace (MEDP) Stock Price

News coverage about Medpace (NASDAQ:MEDP) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medpace earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.1859512369285 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Medpace (NASDAQ MEDP) opened at $36.58 on Monday. The stock has a market capitalization of $1,375.63, a price-to-earnings ratio of 24.88, a P/E/G ratio of 1.87 and a beta of -0.34. Medpace has a fifty-two week low of $21.76 and a fifty-two week high of $39.64. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.36.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.04. The firm had revenue of $98.68 million during the quarter, compared to analyst estimates of $96.84 million. Medpace had a return on equity of 10.00% and a net margin of 6.44%. Medpace’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business posted $0.40 earnings per share. research analysts anticipate that Medpace will post 1.5 EPS for the current year.

MEDP has been the subject of several research analyst reports. Zacks Investment Research upgraded Medpace from a “sell” rating to a “hold” rating and set a $33.00 price target for the company in a research report on Thursday, August 3rd. Jefferies Group LLC restated a “hold” rating and set a $31.00 price target (up from $30.00) on shares of Medpace in a research report on Wednesday, August 2nd. Robert W. Baird raised their price target on Medpace from $32.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 31st. William Blair lowered Medpace from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 1st. They noted that the move was a valuation call. Finally, KeyCorp restated a “hold” rating on shares of Medpace in a research report on Tuesday, October 17th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Medpace presently has a consensus rating of “Hold” and a consensus target price of $36.60.

TRADEMARK VIOLATION WARNING: This piece was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at

About Medpace

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with's FREE daily email newsletter.

Leave a Reply